Insider: ABERNETHY MATT Chief Financial Officer - NEUROCRINE BIOSCIENCES INC
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 34,775 | 0 | 34,775 |
| Value | $4,899,449.75 | $0.00 | $4,899,449.75 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 02/13/2025 | DDS | 1,352 | Direct | COM | $116.85 | $157,979.44 | 34,775 |
| 02/13/2025 | DDS | 1,206 | Direct | COM | $116.87 | $140,943.77 | 35,810 |
| 02/10/2025 | DDS | 980 | Direct | COM | $118.27 | $115,908.52 | 33,561 |
| 01/31/2025 | DDS | 1,283 | Direct | COM | $152.87 | $196,135.80 | 32,681 |
| 08/13/2024 | DDS | 14,100 | Direct | COM | $150.38 | $2,120,346.72 | 31,528 |
| 05/15/2024 | DDS | 15,000 | Direct | COM | $140.24 | $2,103,609.00 | 31,528 |
| 05/14/2024 | DDS | 15,000 | Direct | COM | $135.66 | $2,034,826.50 | 31,528 |
| 02/13/2024 | DDS | 1,352 | Direct | COM | $132.85 | $179,611.58 | 31,528 |
| 02/08/2024 | DDS | 980 | Direct | COM | $134.21 | $131,529.23 | 30,314 |
| 02/06/2024 | DDS | 1,280 | Direct | COM | $142.19 | $182,000.38 | 29,434 |
| 01/31/2024 | DDS | 1,283 | Direct | COM | $140.72 | $180,538.76 | 28,284 |
| 08/21/2023 | DDS | 2,132 | Direct | COM | $107.39 | $228,958.46 | 27,131 |
| 02/08/2023 | DDS | 980 | Direct | COM | $104.19 | $102,110.02 | 25,213 |
| 02/07/2023 | DDS | 12,807 | Direct | COM | $102.42 | $1,311,687.82 | 35,824 |
| 02/07/2023 | DDS | 2,030 | Direct | COM | $102.33 | $207,725.43 | 24,333 |
| 02/07/2023 | DDS | 11,491 | Direct | COM | $102.40 | $1,176,693.34 | 24,333 |
| 02/06/2023 | DDS | 1,280 | Direct | COM | $105.67 | $135,253.38 | 22,507 |
| 01/31/2023 | DDS | 1,283 | Direct | COM | $109.98 | $141,107.80 | 21,357 |
| 02/08/2022 | DDS | 980 | Direct | COM | $79.65 | $78,057.59 | 20,204 |
| 02/07/2022 | DDS | 1,280 | Direct | COM | $80.78 | $103,396.10 | 19,325 |
| 02/07/2022 | DDS | 2,030 | Direct | COM | $80.80 | $164,032.12 | 18,175 |
| 12/01/2021 | DDS | 1,645 | Direct | COM | $82.59 | $135,852.49 | 16,349 |
| 02/08/2021 | DDS | 880 | Direct | COM | $116.85 | $102,825.54 | 13,043 |
| 02/08/2021 | DDS | 2,030 | Direct | COM | $116.81 | $237,115.98 | 14,869 |
| 11/12/2020 | DDS | 2,257 | Direct | COM | $90.74 | $204,810.11 | 10,014 |
| 1 2 Next Last You are at page 1 of 2 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research